Concepedia

Author

Jonathan Wadsley

Weston Park Cancer CentreORCID

Also Known As

J C Wadsley, J Wadsley, J. Wadsley, J.C. Wadsley, John Wadsley, Johnathan Wadsley, Jon Wadsley, Jonathan C. Wadsley, Jonathan Charles Wadsley, Jonathan Wadsley

190

Publications

11.6K

Citations

35

H-Index

70

Concepts

All Affiliations

Weston Park Cancer CentreRoyal Marsden HospitalThe Christie NHS Foundation TrustUniversity College LondonVelindre Cancer Centre
JW

About

Jonathan Wadsley is an author at Weston Park Cancer Centre specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

34

5.5K

2

Health Sciences

14

16

3.1K

3

Public Health

1

1

52

4

Biostatistics

1

1

15

5

Cell Biology

1

1

137

Jonathan Wadsley

×

62

Publications

9.9K

Citations

32

H-Index

YearCitations

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh,

The Lancet

2017

1.9K

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

John Primrose, Richard Fox, Daniel H. Palmer,

The Lancet Oncology

2019

1.2K

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González,

The Lancet Oncology

2013

723

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan,

The Lancet Oncology

2021

711

Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer

Ujjal K. Mallick, Clive Harmer, B. Yap,

New England Journal of Medicine

2012

606

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Andrea Marshall, John Bridgewater,

The Lancet Oncology

2013

597

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Sarah Brown, Gary Middleton, Tim Maughan,

The Lancet Oncology

2013

388

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

Gary Middleton, Paul Silcocks, Trevor F. Cox,

The Lancet Oncology

2014

370

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Paula Ghaneh, Daniel H. Palmer, Silvia Cicconi,

˜The œLancet. Gastroenterology & hepatology

2022

294

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

Page 1